Physician profile
Chris Noyes
NPI 1205803400
$7,204.55
in general payments reported to CMS, 2019-2025
46 companies · $1,890 in 2025
The $1,890 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $817 · 2021: $478 · 2022: $971 · 2023: $1,433 · 2024: $459 · 2025: $1,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266 · Consulting Fee: $1,500 · Entertainment: $16.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,265.89 |
| Consulting Fee | $1,500.00 |
| Entertainment | $16.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,689.10 | 2019-2025 | Amplatzer Amulet, Freestyle Libre 3, Penta |
| Novo Nordisk INC | $909.42 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $709.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $558.27 | 2019-2023 | |
| Amgen INC. | $315.09 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $284.53 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.71 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $250.60 | 2019-2023 | Steglatro, Belsomra, Verquvo |
| Exact Sciences Corporation | $183.57 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $181.88 | 2019-2023 | Airsupra |
| Inari Medical, INC. | $181.59 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Glaxosmithkline, LLC. | $167.85 | 2019-2023 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $133.12 | 2022-2023 | |
| Currax Pharmaceuticals LLC | $124.86 | 2019-2025 | Contrave, Nexlizet, Onzetra Xsail |
| Si-Bone, INC. | $121.69 | 2019-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Noyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.